Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?

Blue shape

You might also be interested in...

September 18, 2024

Tr1X to Participate at Upcoming Healthcare Investment Conferences

View

View

August 7, 2024

Tr1X Announces FDA Clearance of IND Application for TRX103, an Allogeneic Engineered Tr1 Treg Cell Therapy for Treatment-Refractory Crohn’s Disease.

View

View

November 10, 2022

Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases

View

View